Research Frontiers (NasdaqCM:REFR) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Speaker4Good afternoon. Welcome to Research Frontiers investor conference call to discuss the fourth quarter and year-end 2025 results of operations and recent developments. The company will be answering many of the questions that were emailed to it prior to this conference call, either in their presentation or as part of the Q&A session at the end. In some cases, the company has responded directly to email questions prior t ...

Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash and investments of $301.8 million, indicating a strong financial position to support ongoing clinical programs [24] - The funds expended in 2025 were primarily directed towards the advancement of the HCV Phase 3 program and discovery efforts for HEV treatment [24] - R&D expenses increased in 2025 compared to 2024, driven by external spending on the HCV Phase 3 clinical development [25] Business Line Data and Key Metrics Changes - The global Phase 3 HCV program is on track, with enrollment completed for the North American trial, C-BEYOND, involving over 880 patients [6] - The company anticipates top-line results for C-BEYOND by mid-year and for C-FORWARD by year-end [6][27] - The HEV program has been initiated with AT-587 as the lead product candidate, with plans to start a first-in-human study mid-year [6][27] Market Data and Key Metrics Changes - The incidence of new chronic Hepatitis C infections in the U.S. has increased to approximately 4 million, with only 85,000 patients treated annually [8] - The market opportunity for chronic HEV treatment is estimated to be between $750 million and $1 billion per year, addressing a significant unmet need [20] Company Strategy and Development Direction - The company aims to deliver top-line Phase 3 results for HCV treatments that feature high efficacy, short treatment duration, and low risk of drug-drug interactions [27] - The HEV program represents a strategic expansion of the antiviral pipeline, targeting a vulnerable patient population with no approved treatments available [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving enrollment targets for both C-BEYOND and C-FORWARD trials, indicating a robust clinical development strategy [30] - The company is focused on maintaining financial discipline while advancing its HCV and HEV product candidates, projecting a cash runway extending through 2027 [25][26] Other Important Information - The company returned $25 million to stockholders through a share repurchase program in 2025, reflecting a commitment to drive value for stockholders [24] - The commercial package for HCV will include a blister card for convenience and adherence, with a simple 4-week dosing regimen [17] Q&A Session Summary Question: Does achieving enrollment targets for the cirrhotic population for C-BEYOND increase confidence in C-FORWARD? - Management confirmed that they are on track to achieve overall targets for both trials, with cirrhotic enrollment not being an issue [30] Question: Can you discuss the commercial landscape and pricing evolution for HCV treatments? - Management indicated that the specialty market for DAA is well understood, with stable pricing trends and positive interest from payers regarding the new regimen [34][35] Question: How does the primary endpoint analysis for C-BEYOND affect the potential market uptake? - Management noted that the modified intent-to-treat analysis allows for flexibility in dosing, and the positive profile of the regimen is expected to resonate well with prescribers [39][40]

Financial Data and Key Metrics Changes - Fourth quarter revenues were $13.2 million, representing a 60% increase year-over-year, while full-year revenues were $45.2 million, a 53% increase compared to the previous year [5][21] - Gross margin for the fourth quarter improved to 87% from 85% in the prior year, driven by better manufacturing efficiency [21] - Net operating loss for the quarter was $3.3 million, down from $7.6 million in the prior year, reflecting increased revenue and margin contribution [22] - Adjusted EBITDA loss for the quarter was approximately $950,000, an improvement from a loss of $5.7 million in the prior year [22] Business Line Data and Key Metrics Changes - Revenue from the TriNav system for the year was $45 million, a 53% increase compared to the previous year, primarily driven by increased sales in liver-directed therapies [23] - Research and development expenses decreased by $2.7 million for the year, mainly due to the closeout of clinical trial expenses related to nelitolimod [24] - Sales and marketing expenses increased by $2.9 million for the year, attributed to higher performance-related compensation due to increased sales [24] Market Data and Key Metrics Changes - The total addressable market for liver embolization procedures is approximately $480 million, while the broader embolization market represents a $2.3 billion opportunity [13][14] - The introduction of a new CMS HCPCS code expanded coverage for simulation or mapping procedures using TriNav, effectively doubling the reimbursable use of the technology [14][15] Company Strategy and Development Direction - The primary strategic priority is to expand sales and commercial infrastructure, with plans to double the commercial footprint and enhance clinical studies to validate the PEDD platform [7][9] - The company aims to launch TriNav Advance in the first half of 2026, which is expected to facilitate selective therapy delivery to small distal vessels [13] - The strategy includes conducting foundational studies to prove the superiority of the technology in liver embolization, which is expected to drive long-term penetration in the market [55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $60 million to $62 million for 2026, with growth weighted towards the second half of the year [9][19] - The company noted strong physician engagement and interest in the PEDD platform, indicating a positive outlook for future demand [10] - Management emphasized the importance of investing in commercial infrastructure and clinical evidence to support long-term growth [7][20] Other Important Information - The company raised $46 million in gross proceeds through a public offering, which was oversubscribed and supported by experienced healthcare investors [6][26] - The company is focused on executing near-term milestones, including launching TriNav Advance and publishing clinical data across various indications [19][20] Q&A Session Summary Question: Contribution from liver versus non-liver growth in 2026 - Management indicated that liver will still be the majority of revenue in 2026, with expectations for meaningful progress in non-liver applications tied to data releases later in the year [28][29] Question: Balancing growth cadence and EBITDA pathway - Management stated that specific timing or guidance on cash flow breakeven or adjusted EBITDA breakeven is not being provided at this time, as investments in commercial expansion are ongoing [30] Question: Details on the sales organization structure after investments - Management confirmed that the commercial organization will be significantly expanded, including adding a layer of management to improve sales opportunities [34][35] Question: Growth expectations for mapping and simulation - Management expressed confidence in growth from mapping and simulation, particularly with the introduction of new products like TriNav XP and TriNav Advance [40][41] Question: Use patterns for the TriNav product portfolio - Management noted varied use patterns among physicians, with some preferring specific products while others seek access to the full portfolio for clinical flexibility [48][52] Question: Long-term opportunities for TriNav in liver versus non-liver - Management highlighted that liver will remain a significant component of sales, but there are substantial growth opportunities in non-liver applications, particularly in thyroid artery embolization [54][56]

Financial Data and Key Metrics Changes - Omada Health achieved a 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][29] - The total number of members increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - The company achieved its first quarter of positive GAAP net income in Q4, reporting $5 million, and delivered positive full-year adjusted EBITDA of $6 million [4][34] Business Line Data and Key Metrics Changes - Revenue from the weight health program grew more than 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][69] - The GLP-1 Care Track saw significant adoption, with over 150,000 members supported on GLP-1s, and members on average achieved greater weight loss compared to published real-world evidence [10][11] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million estimated eligible lives [18] - The company noted strong performance across multiple channels, including a successful launch of a large new channel partner [17] Company Strategy and Development Direction - Omada Health is focused on expanding its multi-condition platform, which includes weight health, diabetes, hypertension, and cholesterol management, to provide integrated care solutions [8][24] - The company aims to leverage AI to enhance member support and operational efficiency, embedding AI throughout its services [12][66] - The strategy includes maintaining a balance between growth and profitability, targeting long-term adjusted EBITDA margins of over 20% [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with momentum and a clear plan, highlighting the strong market demand for chronic care solutions and AI-driven innovation [4][5] - The company anticipates 2026 revenue in the range of $312 million to $322 million, reflecting a 22% growth over 2025 [36][37] Other Important Information - Omada Health's GAAP gross margin improved to 71% in Q4, up from 67% in the prior year, and adjusted gross margin reached an all-time high of 73% [30][31] - The company ended 2025 with $222 million in cash and cash equivalents, having generated positive operating cash flow for the year [36] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business contributions and does not include new opportunities like GLP-1 prescribing or FlexCare, which could provide upside [42][46] Question: How did January and February track in terms of conversions? - Management reported strong performance in closing additional eligible covered lives and improved enrollment rates, indicating positive trends early in 2026 [48] Question: What is the impact of the new GLP-1 FlexCare program on economics? - The FlexCare program allows employers to support employees with structured models for GLP-1 access, which includes compensation for Omada for facilitating connections [53][56] Question: How is Omada leveraging AI to improve operations? - Omada is utilizing AI for member support and operational efficiencies, with a focus on unique data sets that enhance personalized care [65][66] Question: What traction is being seen in hypertension and diabetes programs? - Management noted strong growth in both diabetes and hypertension programs, reflecting the integrated cardiometabolic care approach [68][69]

Traeger (NYSE:COOK) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Speaker3Good afternoon. Thank you for attending today's Traeger's fourth quarter and full year 2025 earnings conference call. My name is Megan, I'll be your moderator for today. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question during that time, simply press star one on your telephone keypad. I would now like to pass the conferen ...

Financial Data and Key Metrics Changes - In Q4 2025, adjusted EBITDA increased by $2.2 million or 17.1% to $15.2 million compared to $13 million in Q4 2024 [4] - Q4 revenue was $90.9 million, a 4% decrease from the prior year period, but excluding flight equipment sales, revenue increased by 9.8% [4][5] - For the full year 2025, total revenue was $335.3 million, a decrease of $9.8 million or 2.8% year-over-year, primarily due to fewer flight equipment sales [6] - Full year adjusted EBITDA increased by $12.8 million to $46.1 million, up 38.2% year-over-year [6][19] Business Line Data and Key Metrics Changes - Asset Management revenue in Q4 declined approximately 11.1% year-over-year to $56.9 million due to fewer flight equipment sales, but excluding these sales, revenue increased by 9.1% [15][16] - TechOps revenue in Q4 increased by 10.7% to $34 million, driven by higher sales in aerostructures and landing gear MROs [16] - For the full year, TechOps revenue declined 4.5% to $123.7 million, primarily due to lower on-airport MRO activity, but gross margin improved to 25.6% from 16.6% in the prior year [17] Market Data and Key Metrics Changes - The company ended 2025 with a win rate of 4.8% in feedstock acquisitions, down from 17.2% in Q4 2024, indicating a hyper-competitive market [7] - The company has approximately $364 million of inventory at the start of 2026, with $150 million ready for deployment in the USM channel [27] Company Strategy and Development Direction - The company aims to mitigate earnings volatility by growing more recurring and predictable parts of the business, including expanding USM sales and leasing [11] - Strategic adjustments in MRO facilities have been made to improve profitability, including transitioning contracts to higher rates and focusing on storage and end-of-life fleet activities [9][10] - The company is committed to the success of its Enhanced Flight Vision System, AerAware, and is actively marketing it to both commercial and governmental customers [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving growth in 2026, supported by efficiency initiatives and a strong balance sheet [12] - The company anticipates steady incremental improvements as new revenue streams ramp up and efficiency initiatives continue to gain traction [20] - Management noted that the market for feedstock remains hyper-competitive, and they will remain disciplined in their purchasing strategy [24] Other Important Information - The company received FAA approval to overhaul Boeing 737 MAX and 787 landing gear, expanding its capabilities to support a growing customer base [10] - The company expects that the full capacity potential of its expansion initiatives will exceed previous estimates of approximately $50 million in annualized opportunity [10] Q&A Session Summary Question: What is the goal for material feedstock purchases this year? - Management anticipates a lower level of feedstock purchases this year than last year due to a hyper-competitive market [22][23] Question: How much inventory is available for monetization? - The company has ample inventory to continue growth without needing to buy as much as last year, with $364 million in inventory at the start of 2026 [27][28] Question: How will GTF normalization and AerSafe deadline impact future revenues? - Management does not expect GTF normalization in 2026 and sees opportunities in returning parked aircraft to service, while AerSafe sales are expected to peak this year [29][31][46]

Grid Dynamics (NasdaqCM:GDYN) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Speaker4Joining us on the call today are CEO Leonard Livschitz, CFO Anil Doradla, CTO Eugene Steinberg, COO Yury Gryzlov, and SVP Head of Americas Vasily Sizov. Following the prepared remarks, we will open the call to your questions. Please note that today's conference call is being recorded. Before we begin, I would like to remind everyone that today's discussion will contain forward-looking statements. This includes our busines ...

Financial Data and Key Metrics Changes - In 2025, AudioEye achieved record revenue growth for the 40th consecutive quarter, with adjusted EBITDA growing by approximately 35% to a record $9.1 million, representing a margin of 22% [4][17] - Q4 2025 revenue reached $10.5 million, an 8% increase from Q4 2024, and a 10% annualized increase from Q3 2025 [11] - For the full year 2025, revenue grew 15% to $40.3 million from $35.2 million in 2024 [11] - Net loss in Q4 2025 was $1.1 million or $0.08 per share, compared to a net loss of $1.5 million or $0.12 per share in the same period last year [16] Business Line Data and Key Metrics Changes - The partner and marketplace channel grew 8% year-over-year in Q4 2025, representing approximately 59% of ARR, with full-year revenue increasing 10% to $22.2 million [11][12] - The enterprise channel grew 8% in Q4 2025 and 21% for the full year, reaching $18.1 million, driven by expansion into the EU [12] - Annual recurring revenue (ARR) at the end of Q4 2025 was $40 million, a 9% increase over the previous year [13] Market Data and Key Metrics Changes - The company anticipates that 2026 will see the highest year of digital accessibility lawsuits on record, driven by increased litigation utilizing AI to detect accessibility issues [6] - The EU market is expected to ramp up as enforcement of regulations increases, with significant deals in the pipeline [29] Company Strategy and Development Direction - AudioEye's next-generation platform aims to unify AI detection, expert audits, and custom fixes, providing unmatched transparency and legal protection [6][7] - The company is focusing on accelerating ARR growth while reducing reliance on non-recurring revenue, with guidance for 2026 indicating revenue growth of between $43 million and $44.5 million [9][25] - The company is leveraging proprietary data to enhance its platform and drive future growth opportunities [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position, citing a unique data advantage and the potential for significant growth in the accessibility market [24][32] - The company expects adjusted EBITDA to grow by at least 30% in 2026, with a run rate of $15 million by year-end [5][9] Other Important Information - The company repurchased approximately $4.6 million worth of shares in 2025, strengthening its balance sheet [17] - As of December 31, 2025, the company had $5.3 million in cash and $6.6 million in available debt facilities [18] Q&A Session Summary Question: Update on platform updates and human involvement in custom fixes - Management indicated that while AI tools are improving, significant human involvement will still be necessary due to the complexity of accessibility issues [20] Question: Revenue guidance for 2026 and factors influencing it - Management noted that the guidance reflects a conservative approach, focusing on ARR growth and reducing non-recurring revenue [23][25] Question: Update on investments in the EU and opportunities - Management confirmed ongoing pipeline development in the EU, with expectations for increased demand as regulatory enforcement ramps up [29] Question: Potential partnerships related to AI - Management highlighted the unique data they possess and the potential for future partnerships, though specific strategies were not disclosed [31] Question: Update on DOJ Title II enforcement - Management confirmed that DOJ requirements are set to go into effect soon, with strong momentum observed from partners [34] Question: Thoughts on gross margin expectations for 2026 - Management expects gross margins to remain consistent, with potential for growth as AI compute costs are managed [35]

Lineage Cell Therapeutics (NYSEAM:LCTX) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Speaker7Welcome to the Lineage Cell Therapeutics 3rd quarter 2025 conference call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investors section of Lineage website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage. Any recordings, reproductions or transmissions of this call without the express written consent of Lineag ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $32.2 million, with adjusted EBITDA of $12 million, exceeding both consensus estimates and internal expectations [3][12] - Full year revenue totaled $109.4 million, with adjusted EBITDA of $24.3 million, demonstrating the strength of the operating model [3][5] - Gross margin increased from 68.1% in Q4 2024 to 74.8% in Q4 2025, attributed to a favorable product mix and channel partner strategy [13][14] - Net income for Q4 2025 was $5 million, or $0.26 per diluted share, compared to a net loss of $0.1 million in Q4 2024 [15] - Cash and short-term investments increased to $23.4 million as of December 31, 2025, from $13.4 million a year earlier [16] Business Line Data and Key Metrics Changes - The average revenue per top 20 pharmaceutical manufacturer declined slightly from $3 million in 2024 to $2.8 million in 2025, primarily due to lower buy-ups and data-related revenue [17] - The net revenue retention rate remained strong at 116%, indicating solid customer retention and growth [17] Market Data and Key Metrics Changes - There is a noted softness in year-to-date contracted revenue numbers compared to the previous year, driven by a market shift away from managed services [4][5] - The company is seeing a broader pause across clients as they adjust to Most-Favored-Nation pricing negotiations, impacting spending behavior [21][22] Company Strategy and Development Direction - The company is focused on transitioning more customers to a subscription-based model to enhance revenue predictability and establish a consistent recurring revenue component [87] - A $10 million share repurchase program has been authorized, reflecting confidence in the long-term value of the business [6] - The company aims to capture additional market share within the pharma industry's multi-billion dollar digital ecosystem, emphasizing its role as a strategic partner [11][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the current market softness is temporary and expects normalization in spending behavior over the coming months [5][21] - The guidance for 2026 has been updated to reflect a more conservative revenue outlook, with expectations of $109 million to $114 million [5][17] - Management believes there is significant opportunity for value creation, particularly in the mid-tier and long-tail life science companies [3][5] Other Important Information - The company has experienced minimal disruption from AI and views it as a potential tailwind, enabling clients to reallocate marketing budgets towards execution rather than content creation [6][28] - The company is uniquely positioned with a comprehensive commercialization platform that integrates advanced patient-finding capabilities [10][11] Q&A Session Summary Question: Are you seeing conservatism only with the companies in MFN negotiations or is it broader? - Management noted a broader pause across all clients as they digest the implications of MFN negotiations, leading to shorter contract durations [21] Question: Are there nuances between DTC and HCP marketing pressures? - Management indicated that both DTC and HCP marketing are experiencing similar pressures from manufacturers [22] Question: Can you elaborate on the gross margin drivers and sustainability? - Management explained that Q4 2025 had a favorable mix of channel partners driving higher margins, but does not expect this level to be sustainable throughout 2026 [23][25] Question: How is AI impacting operations? - Management stated that AI is creating efficiencies and enabling clients to focus more on commercial execution rather than content creation [27][28] Question: What is the current percentage of revenue under contract? - Management indicated that they are running approximately 15%-20% behind last year's contracted revenue numbers due to shorter contract durations [34][36] Question: What is the guidance for managed services in 2026? - Management stated that the guidance includes very little from managed services, as it is considered an episodic solution [40] Question: What strategies are being employed to capture mid-tier and smaller manufacturers? - Management highlighted the ability to supplement the marketing efforts of mid-tier and long-tail clients, filling gaps in their infrastructure [45][46] Question: How will capital be deployed between debt repayment and share buybacks? - Management indicated that they will evaluate opportunities as they arise, with a historical focus on paying down debt with excess cash flow [49] Question: What are the expectations for net revenue retention in 2026? - Management aims for a net revenue retention rate above 100%, indicating a positive outlook for customer retention [50]